These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 21737347

  • 1. Targeting Plasmodium liver stages: better late than never.
    Borrmann S, Matuschewski K.
    Trends Mol Med; 2011 Sep; 17(9):527-36. PubMed ID: 21737347
    [Abstract] [Full Text] [Related]

  • 2. Harnessing immune responses against Plasmodium for rational vaccine design.
    Douradinha B, Doolan DL.
    Trends Parasitol; 2011 Jun; 27(6):274-83. PubMed ID: 21531627
    [Abstract] [Full Text] [Related]

  • 3. Whole parasite vaccination approaches for prevention of malaria infection.
    Butler NS, Vaughan AM, Harty JT, Kappe SH.
    Trends Immunol; 2012 May; 33(5):247-54. PubMed ID: 22405559
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite.
    Friesen J, Matuschewski K.
    Vaccine; 2011 Sep 16; 29(40):7002-8. PubMed ID: 21787828
    [Abstract] [Full Text] [Related]

  • 5. Exoerythrocytic malaria vaccine development: understanding host-parasite immunobiology underscores strategic success.
    Taylor-Robinson AW.
    Expert Rev Vaccines; 2002 Oct 16; 1(3):317-40. PubMed ID: 12901572
    [Abstract] [Full Text] [Related]

  • 6. Malaria vaccine.
    Khurana SK, Talib VH.
    Indian J Pathol Microbiol; 1996 Dec 16; 39(5):433-41. PubMed ID: 9002371
    [Abstract] [Full Text] [Related]

  • 7. Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies.
    Good MF.
    Trends Immunol; 2005 Jun 16; 26(6):295-7. PubMed ID: 15922944
    [Abstract] [Full Text] [Related]

  • 8. A whole parasite vaccine to control the blood stages of Plasmodium: the case for lateral thinking.
    Good MF.
    Trends Parasitol; 2011 Aug 16; 27(8):335-40. PubMed ID: 21514227
    [Abstract] [Full Text] [Related]

  • 9. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine.
    Mueller AK, Labaied M, Kappe SH, Matuschewski K.
    Nature; 2005 Jan 13; 433(7022):164-7. PubMed ID: 15580261
    [Abstract] [Full Text] [Related]

  • 10. Protective immunity against malaria by 'natural immunization': a question of dose, parasite diversity, or both?
    Borrmann S, Matuschewski K.
    Curr Opin Immunol; 2011 Aug 13; 23(4):500-8. PubMed ID: 21719266
    [Abstract] [Full Text] [Related]

  • 11. Preerythrocytic malaria vaccine development.
    Mikolajczak SA, Aly AS, Kappe SH.
    Curr Opin Infect Dis; 2007 Oct 13; 20(5):461-6. PubMed ID: 17762778
    [Abstract] [Full Text] [Related]

  • 12. Cross-stage immunity for malaria vaccine development.
    Nahrendorf W, Scholzen A, Sauerwein RW, Langhorne J.
    Vaccine; 2015 Dec 22; 33(52):7513-7. PubMed ID: 26469724
    [Abstract] [Full Text] [Related]

  • 13. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice.
    Aly AS, Downie MJ, Mamoun CB, Kappe SH.
    Cell Microbiol; 2010 Jul 22; 12(7):930-8. PubMed ID: 20088947
    [Abstract] [Full Text] [Related]

  • 14. Vaccine development against malaria.
    Matuschewski K.
    Curr Opin Immunol; 2006 Aug 22; 18(4):449-57. PubMed ID: 16765576
    [Abstract] [Full Text] [Related]

  • 15. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells.
    Tarun AS, Dumpit RF, Camargo N, Labaied M, Liu P, Takagi A, Wang R, Kappe SH.
    J Infect Dis; 2007 Aug 15; 196(4):608-16. PubMed ID: 17624848
    [Abstract] [Full Text] [Related]

  • 16. Immune responses to liver-stage parasites: implications for vaccine development.
    Hollingdale MR, Krzych U.
    Chem Immunol; 2002 Aug 15; 80():97-124. PubMed ID: 12058653
    [No Abstract] [Full Text] [Related]

  • 17. Vaccination using radiation- or genetically attenuated live sporozoites.
    Vaughan AM, Kappe SH.
    Methods Mol Biol; 2013 Aug 15; 923():549-66. PubMed ID: 22990804
    [Abstract] [Full Text] [Related]

  • 18. Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines.
    Saxena AK, Wu Y, Garboczi DN.
    Eukaryot Cell; 2007 Aug 15; 6(8):1260-5. PubMed ID: 17557884
    [No Abstract] [Full Text] [Related]

  • 19. Asexual blood-stage malaria vaccine development: facing the challenges.
    Genton B, Reed ZH.
    Curr Opin Infect Dis; 2007 Oct 15; 20(5):467-75. PubMed ID: 17762779
    [Abstract] [Full Text] [Related]

  • 20. Chimeric parasites as tools to study Plasmodium immunology and assess malaria vaccines.
    Cockburn I.
    Methods Mol Biol; 2013 Oct 15; 923():465-79. PubMed ID: 22990798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.